Key result
Seven FDA-approved aortic endografts are currently available for abdominal aortic aneurysms, though secondary interventions and follow-up requirements remain a significant issue.
Despite the availability of seven FDA-approved aortic endografts with advanced designs for EVAR, technical complications like endoleaks and the need for secondary interventions remain significant clinical challenges.
Endovascular Aneurysm Repair is a widely adopted method of treatment for patients with abdominal aortic aneurysms. The minimally invasive approach offered with EVAR has become popular not only among physicians and patients, but in the medical device industry as well. Over the past 25 years the global market for aortic endografts has increased rapidly, resulting in a wide range of devices from various companies. Currently, there are seven endografts approved by the FDA for the treatment of abdominal aortic aneurysms. These devices offer a wide range of designs intended to increase inclusion criteria while decreasing technical complications such as endoleak and migration. Despite advances in device design, secondary interventions and follow-up requirements remain a significant issue. New devices are currently being studied in the U.S. and abroad and may significantly reduce complications and secondary interventions.
No takes yet. Share an insight, caveat, or question.
Colvard et al. (2016) conducted a review in abdominal aortic aneurysms. Aortic endografts (EVAR) was evaluated. Seven FDA-approved aortic endografts are currently available for abdominal aortic aneurysms, though secondary interventions and follow-up requirements remain a significant issue.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: